Terms: = Leukemia AND HNRNPA2B1, ENSG00000122566, SNRPB1, RNPA2, HNRPB1, HNRPA2, HNRNPB1, HNRNPA2, 3181 AND Prognosis
4 results:
1. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
Fan J; Zhuang M; Fan W; Hou M
PeerJ; 2023; 11():e15706. PubMed ID: 37663284
[TBL] [Abstract] [Full Text] [Related]
2. N6-methyladenosine in hematological malignancies: a concise review.
Wang WJ; Xu TT; Bao J
Curr Opin Hematol; 2023 Jan; 30(1):4-13. PubMed ID: 36165537
[TBL] [Abstract] [Full Text] [Related]
3. [Establishment and validation of prognosis predictive model using m
Xu JR; Yang DH; Long GF; Sun H; Chen HB
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Aug; 55(8):983-989. PubMed ID: 34445837
[No Abstract] [Full Text] [Related]
4. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
[TBL] [Abstract] [Full Text] [Related]
